胃肠道恶性肿瘤患者应用重组人生长激素后免疫功能的变化  

EFFECT OF RECOMBINANT HUMAN GROWTH HORMONE ON IMMUNOLOGIC FUNCTION IN PATIENTS WITH GASTROINTESTINAL MALIGNANT TUMOR

作　　者：冉江华[1] 郭群[1] 张家骅[1] 杨炯[1] 王曦[1] 

机构地区：[1]昆明医学院第二附属医院普外科

出　　处：《中国普外基础与临床杂志》1999年第5期298-299,共2页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：为探讨重组人生长激素（ｒｈ Ｇ Ｈ）对胃肠道恶性肿瘤患者免疫功能的影响，对 １２ 例胃肠道恶性肿瘤患者手术前、后及使用重组人生长激素后外周血 Ｔ 淋巴细胞亚群（ Ｔ Ｌ Ｓ）和血清可溶性白介素２ 受体（ｓ Ｉ Ｌ２ Ｒ）进行了检测，并与１８ 例未使用ｒｈ Ｇ Ｈ 的胃肠道恶性肿瘤患者及 ２０ 例健康人进行比较。结果： ①胃肠道恶性肿瘤患者 Ｔ 淋巴细胞亚群中 Ｃ Ｄ＋３ 、 Ｃ Ｄ＋４ 细胞减少， Ｃ Ｄ＋４ ／ Ｃ Ｄ＋８ 细胞比值下降，ｓ Ｉ Ｌ２ Ｒ水平升高； ②手术切除肿瘤后， Ｃ Ｄ＋３ 、 Ｃ Ｄ＋４ 细胞增加， Ｃ Ｄ＋４ ／ Ｃ Ｄ＋８细胞比值升高，ｓ Ｉ Ｌ２ Ｒ 水平降低； ③使用 ｒｈ Ｇ Ｈ 后， Ｃ Ｄ＋３ 、 Ｃ Ｄ＋４ 细胞与未使用 ｒｈ Ｇ Ｈ 的患者比较有显著性差异， Ｃ Ｄ＋４ ／ Ｃ Ｄ＋８ 细胞比值明显下降（ Ｐ＜ ０．０１），ｓ Ｉ Ｌ２ Ｒ 水平也明显降低（ Ｐ＜ ０．０１），并接近正常人。本实验结果提示： 应用ｒｈ Ｇ Ｈ 能增强胃肠道恶性肿瘤患者的免疫功能。To evaluate effect of recombinant human growth hormone (rhGH) on immunologic function in patients with gastrointestinal malignant tumor (GIMT). Before and 3 weeks after surgical treatment and administration of rhGH, the amount of T lymphocyte subset (T LS) and soluble interleukin 2 receptor (sIL 2R) level were measured in 12 patients with GIMT, which were compared with 20 cases of normal control and 18 cases of GIMT treated by surgery alone. Result: ①In all GIMT patients, the serum CD + 3, CD + 4 level and the ratio of CD + 4/CD + 8 were lower than normal control and the sIL 2R level was much higher; ②After operation, the serum CD + 3, CD + 4 level and the ratio of CD + 4/CD + 8 of all patients increased, the serum sIL 2R level decreased; ③In patients recieved rhGH, the serum CD + 3, CD + 4 level and the ratio of CD + 4/CD + 8 were much more increased and the serum sIL 2R level much more decreased than those of surgery alone group. Conclusion: rhGH can enhance the immunologic function of patients with GIMT.

关 键 词：重组 人生长激素 胃肠道肿瘤 T淋巴细胞亚群 

分 类 号：R735.05[医药卫生—肿瘤] R730.54[医药卫生—临床医学]